This is a group of highly-accomplished scientists and drug hunters, some whom I have known for many years, said Leslie Sharp, Ph.D., chief scientific officer (CSO) of OncoMyx. We are thrilled to welcome Tobias, Neil, Grant, Ronan, and Dominic to our SAB, and I look forward to working with the team to develop new therapeutic options for cancer patients.

The SAB will be comprised of the following members:

Tobias Bald, Ph.D. is the Head of the Oncology and Cellular Immunology Laboratory at QIMR Berghofer Medical Research Institute. He is a leading expert in tumor immunology with a strong focus on the role of the innate immune system during tumor development, progression and cancer immunotherapy.

Neil Gibson, Ph.D. is President and CEO of PDI Therapeutics and Senior Vice President of COI Pharmaceuticals. Dr. Gibson has more than 30 years of drug development experience and has been involved in the successful discovery, development and commercialization of four approved oncology drugs (including temozolomide, sorafenib, erlotnib, and crizotinib). Dr Gibsons extensive oncology experience includes being CSO of Pfizer Oncology Research Unit, CSO of Regulus Therapeutics and CSO of OSI Pharmaceuticals. Dr. Gibson also serves on the board of TCR2, a new public company focused on T-cell therapies.

Follow this link:
OncoMyx Therapeutics Announces Formation of Scientific Advisory Board - Arizona Daily Star